Metabolic Disease Efficacy Evaluation
GemPharmatech performs a variety of metabolic efficacy tests, including glycated hemoglobin assays, glucose and insulin tolerance tests, metabolic cage tests, and blood biochemistry analyses. We have developed a series of mice strains with several metabolic diseases, including obesity, diabetes, metabolic dysfunction-associated steatohepatitis (MASH), and hyperlipidemia, as well as simulated human diseases by medication induction and feeding manipulation. Based on these models, we conduct research on the pathophysiology of associated disorders, drug screening, and efficacy evaluation.
-
Obesity Models and Efficacy Services
Obesity refers to a type of metabolic disorder impacted by factors such as diet, environment, and heredity. In addition to weight gain, obesity is strongly correlated with diseases such as diabetes, hypertension, hyperlipidemia, and cardiovascular events. GemPharmatech has developed a series of obese mouse models, including diet-induced obesity models and spontaneous obesity models caused by genetic mutations, to investigate the mechanism of obesity and evaluate the related therapeutic drugs, helping to provide drug efficacy evaluation services based on these models.
-
Type II Diabetes Models and Efficacy Service
Diabetes mellitus is a common disease caused by genetic, environmental, and immunological factors resulting in islet hypofunction and insulin resistance, and revealing complex metabolic disorders involving sugar, protein, fat, water, and electrolytes. More than 90% of patients with diabetes have type II diabetes(T2D). GemPharmatech has generated the matching diabetes mellitus models using gene-editing technology and a diet-induced modeling approach for researching type II diabetes mellitus pathogenesis as well as evaluating therapeutic medication screening.
-
Type I Diabetes Models and Efficacy Services
-
Androgenetic Alopecia (AGA) Models and Efficacy Services
-
MASH Models and Efficacy Services
-
Chronic Liver Fibrosis Models and Efficacy Services
The liver is an essential hub for material and energy metabolic processes. The impact of alcohol, drugs, and toxic chemicals usually produces acute or chronic liver injury, which can progress to liver fibrosis, cirrhosis, or liver cancer if not appropriately managed. Consequently, experimental animal models of liver disease are essential for investigating the pathophysiology of liver disease and screening therapeutic medicines.GemPharmatech offers liver fibrosis models, metabolic dysfunction-associated steatohepatitis models, and related-efficacy evaluation services.
-
Acute Liver Injury Models and Efficacy Services
-
Cholestasis Models and Efficacy Services
-
Alcohol-related Liver Disease (ALD) Models and Efficacy Services
Alcohol-associated liver disease (ALD) is one of the leading causes of preventable liver-related morbidity and mortality worldwide. To better model disease progression and aid in the evaluation of potential therapeutic targets, GemPharmatech has developed an experimental mouse model of ALD that mimics the histopathological features of the disease.
-
Gout/Hyperuricemia Models and Efficacy Services
Hyperuricemia is a common purine metabolic disorder caused by excessive synthesis or decreased excretion of uric acid as a result of abnormalities in the purine metabolic pathway. A significant risk factor for the development of gout, Hyperuricemia also increases the risk of cardiovascular disease and chronic renal failure. GemPharmatech has developed gout and hyperuricemia models via gene editing and drug induction, and can also provide model-based therapeutic efficacy evaluation services. By injecting uric acid into the local tissues or joints of mice, we have additionally successfully reproduced the symptoms of acute gout in humans.